Know Cancer

or
forgot password

To Excise or Not?: Comparing Clinical Management Decisions for Melanoma Between Dermatologists With and Without the Aid of MelaFind


N/A
N/A
N/A
Not Enrolling
Both
Melanoma

Thank you

Trial Information

To Excise or Not?: Comparing Clinical Management Decisions for Melanoma Between Dermatologists With and Without the Aid of MelaFind


Early detection of melanoma is critical for favorable prognosis, since patients with earlier
stage melanomas have a much higher probability of survival than with later stages. The
traditional method of early detection has been with serial total body skin exams where the
health care provider examines all skin surfaces, including mucosa, for suspicious pigmented
lesions. The diagnostic performance of dermatologists for melanoma depends on the level of
dermatological training. More important than being able to make a diagnosis of melanoma on
clinical impression is the ability to make an appropriate decision to excise the lesion. To
aid dermatologists in the detection of early melanoma, MelaFind was developed, a
non-invasive and objective multi-spectral computer vision system technology. It was
designed to generate output - MelaFind Positive or MelaFind Negative- for consideration in
the lesion management decisions.

This survey study will determine and compare the average excision sensitivity to melanoma
and specificity of dermatologists without MelaFind output to the average excision
sensitivity to melanoma and specificity of dermatologists with MelaFind output. Another
purpose is to determine and compare the sensitivity to melanoma and specificity of MelaFind
to the average excision sensitivity to melanoma and specificity of dermatologists without
MelaFind output.


Inclusion Criteria:



-Only board certified dermatologists

Exclusion Criteria:

-May not have previously participated in MELA Protocols 20061, 20081 or 20063

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Principal Investigator

Axel Hauschild, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dermatologic Cooperative Oncology Group

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

20101

NCT ID:

NCT01387581

Start Date:

October 2011

Completion Date:

March 2012

Related Keywords:

  • Melanoma
  • Melanoma

Name

Location

MELA SciencesIrvington, New York  10533